Mycophenolate mofetil: Implications for the treatment of glomerular disease

Nephrology Dialysis Transplantation

Volumn 16, Issue 9, 2001, Pages 1752-1756

  Badid, Chérif ^a   Desmouliere, Alexis ^b   Laville, Maurice ^a,c  

^a UNIVERSITÉ LYON 1   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Inflammatory glomerular disease; Mycophenolate mofetil

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEOXYGUANOSINE; IMMUNOGLOBULIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NUCLEOTIDE; PROTEIN; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; FOCAL GLOMERULONEPHRITIS; GLOMERULOPATHY; HEYMANN NEPHRITIS; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY ALLOGRAFT; KIDNEY FIBROSIS; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MEMBRANOUS GLOMERULONEPHRITIS; MOUSE; NEPHROTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; SIDE EFFECT; SMOOTH MUSCLE FIBER; VASCULITIS;

EID: 0034839076     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/16.9.1752     Document Type: Article

References (44)

1. Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice
2. Structure and mechanisms of inosine monophosphate deshydrogenase in complex with the immunosuppressant mycophenolic acid
3. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection
4. Inhibition of chronic vascular rejection in primate cardiac xenografts using mycophenolate mofetil
5. Effects of treatment with cyclosporine, FK506, rapamycin, mycophenolic acid or desoxyspergualin on vascular muscle proliferation in vitro and in vivo
6. Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor
7. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection
8. Inhibition of experimental autoimmune uveoretinitis by mycophenolate mofetil, an inhibitor of purine metabolism
9. Mycophenolate mofetil can prevent the development of diabetes in BB rats
10. Preferential suppression of lymphocytes proliferation by mycophenolic acid and predicted long term effects of mycophenolate mofetil in transplantation
11. Pharmacokinetics of mycophenolate mofetil in patients with end stage renal failure
12. Suppression of the humoral immune response by mycophenolate mofetil
13. Reduced human IgG anti-ATGAM antibody formation in renal transplant recipients receiving mycophenolate mofetil
14. Mycophenolic acid and brequinar, inhibitors of purine and pyrimidine synthesis, block the glycosylation of adhesion molecules
15. Treatment with Rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement
16. Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease
17. Attenuation of murine lupus nephritis by mycophenolate
18. Beneficial effect of the inosine monophosphate deshydrogenase inhibitor mycophenolate mofetil on survival and severity of glomerulonephritis in systemic lupus erythematosus prone MRLlpr/lpr mice
19. Mycophenolate mofetil prevents the induction of active Heymann nephritis: Association with Th2 cytokine inhibition
20. Combining an antiproteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals
21. Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats
22. Mycophenolate Mofetil reduces interstitial myofibroblast infiltration and collagen III deposit
23. Mycophenolic acid: A new approach to the therapy of experimental mesangial proliferative glomerulonephritis
24. Effects of mycophenolic acid on human renal proximal an distal tubular cells in vitro
25. Tubular epithelial-myofibroblast transdifferentiation in progressive tubulointerstitial fibrosis in 5/6 nephrectomized rats
26. Combined mycophenolate mofetil and losartan therapy arrests established injury in the remnant kidney
27. Treatment of immunoglobulin A nephropathy
28. Recurrent IgA nephropathy despite mycophenolate mofetil immunosuppression
29. Early and late follow-up of 10 patients with focal segmental glomerulosclerosis undergoing live donor renal transplantation submitted to pre and post transplantation prophylactic plasmapheresis, and triple cyclosporine and mycophenolate mofetil
30. Biopsy-proven resolution of immune complex-mediated crescentic glomerulonephritis with mycophenolate mofetil in an allograft
31. Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide
32. Successful mycophenolate mofetil treatment of glomerular disease
33. Follow-up on mycophenolate treatment of glomerular disease
34. Mycophenolate mofetil therapy in lupus nephritis: Clinical observations
35. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis
36. Comparison of mycophenolate mofetil vs cyclophosphamide pulse therapy in the induction treatment of severe diffuse proliferative lupus nephritis in chinese population
37. Mycophenolate mofetil for systemic vasculitis and IgA nephropathy
38. Mycophenolate mofetil for maintenance therapy of wegener granulomatosis and microscopic polyangeitis: A pilot study in 11 patients with renal involvement
39. Use of mycophenolate mofetil in resistant membranous nephropathy
40. The use of mycophenolate mofetil in children with nephrotic syndrome
41. Mycophenolate mofetil treatment in steroid resistant/relapsing nephrotic syndrome of childhood
42. Mycophenolate mofetil treatment of idiopathic focal segmental glomerulosclerosis
43. Mycophenolate mofetil in steroid resistant focal segmental glomerulosclerosis
44. Control study of effects of mycophenolate mofetil on IgA nephropathy